TOPLINE: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses. METHODOLOGY: GLP-1 RAs are transforming obesity treatment, but high costs and shortages limit patient access. Clinicians have suggested a less frequent dosing to maintain weight loss, but evidence … Read more
TOPLINE: Zimlovisertib plus tofacitinib showed greater efficacy than tofacitinib alone in reducing Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) in patients with rheumatoid arthritis (RA), with a significant reduction observed at week 12. METHODOLOGY: This randomized, phase 2 study, conducted across 77 centers in 10 countries, aimed to evaluate the efficacy, safety, … Read more
Modified antibiotics beat a stubborn lung pathogen and dodge metabolic landmines, offering new hope for patients with HIV, cystic fibrosis, and TB co-infections. Study: Next-generation rifamycins for the treatment of mycobacterial infections. Image Credit: Kateryna Kon / Shutterstock The rise of drug-resistant bacteria is a major health crisis. Moreover, the development of antibiotic resistance in pulmonary pathogens … Read more